msu | June 13, 2020 | 0 Comments |

799-P: Gender Differences in Diabetes Distress Comparing Dapagliflozin plus Saxagliptin to Glimepiride When Added to Metformin in Poorly Controlled Type 2 Diabetes
MARCIA A. TESTA and DONALD C. SIMONSON, Boston, MA Gender Differences in Diabetes Distress Comparing Dapagliflozin plus Saxagliptin to Glimepiride When Added to Metformin.
msu | June 25, 2018 | 0 Comments |

810-P: Patient-reported outcomes in T2D patients inadequately controlled by metformin are more favorable for dapagliflozin plus saxagliptin vs. insulin glargine.
MARCIA A. TESTA, DONALD C. SIMONSON, ELLA EKHOLM, MAXWELL SU, EVA K. JOHNSSON, Boston, MA, Mölndal, Sweden Patient-Reported Outcomes.
msu | June 24, 2018 | 0 Comments |

1520-P:  Impact of Patient-Centered Factors on Comparative Effectiveness of Initial Therapies in Treatment-Naïve T2D
MARCIA A. TESTA, ALEXANDER TURCHIN, MAXWELL SU, DONALD C. SIMONSON, Boston, MA Impact of Patient-Centered Factors on Comparative Effectiveness.
msu | June 23, 2018 | 0 Comments |

941-P: Continuous Glucose Monitoring (CGM) Provides Enhanced Sensitivity Compared with Self-Monitored Blood Glucose (SMBG) for Detecting Hypoglycemia during T2D Clinical Trials.
MARCIA A. TESTA, SERGIO SALDIVAR-SALAZAR, MAXWELL SU, JOHANNA F. HAYES, DONALD C. SIMONSON, Boston, MA, Wellesley Hills, MA Continuous.
msu | June 23, 2018 | 0 Comments |

905-P: Continuous Glucose Monitoring Glycemic Variability Profiles Are More Favorable for Dapagliflozin plus Saxagliptin Compared with Insulin Glargine in Type 2 Diabetes.
DONALD C. SIMONSON, TINA VILSBØLL, ELLA EKHOLM, EVA K. JOHNSSON, MARCIA A. TESTA, SERGE JABBOUR, MARCUS LIND, Boston, MA,.
msu | June 12, 2017 | 0 Comments |

386-OR — 2017 Oral Presentation: A Social Media Learning Collaborative Approach to Competency-Based Training in Diabetes Diabetes Education – Presented Monday – June 12, 2017, SanDiego, CA
MARCIA A. TESTA, SERGIO SALDIVAR-SALAZAR, MAXWELL SU, LINDA G. MARC, DONALD C. SIMONSON, Boston, MA, Wellesley Hills, MA While.